{"id":"NCT00409409","sponsor":"Stallergenes Greer","briefTitle":"Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis","officialTitle":"A Randomised, Double-blind, Placebo-controlled, Multi-national, Multi-centre, Phase III Paediatric Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Children Suffering From Grass Pollen Rhinoconjunctivitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12","primaryCompletion":"2007-09","completion":"2007-09","firstPosted":"2006-12-08","resultsPosted":"2016-05-26","lastUpdate":"2016-05-26"},"enrollment":278,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Allergy"],"interventions":[{"type":"DRUG","name":"300 IR grass pollen allergen extract tablet","otherNames":["Sublingual immunotherapy tablet"]},{"type":"DRUG","name":"Placebo tablet","otherNames":["Sublingual placebo tablet"]}],"arms":[{"label":"300 IR","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A phase III study to evaluate the efficacy and safety of SLIT for grass pollen allergens compared with placebo for reduction of symptoms and rescue medication usage in children.","primaryOutcome":{"measure":"Average Rhinoconjunctivitis Total Symptom Score (ARTSS)","timeFrame":"Pollen period (average of 38.6 days)","effectByArm":[{"arm":"300 IR","deltaMin":3.25,"sd":2.86},{"arm":"Placebo","deltaMin":4.51,"sd":2.931}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0010"}]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":1},"locations":{"siteCount":1,"countries":["Germany"]},"refs":{"pmids":["19046761"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":139},"commonTop":["COUGH","ORAL PRURITUS","NASOPHARYNGITIS","HEADACHE","SNEEZING"]}}